Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria

The development of a unique antibiotic class targeting lipopolysaccharide synthesis, a clinically unexploited target in Gram-negative bacteria, has been identified. The compounds target the lipopolysaccharide synthesis pathway, which is essential in most Gram-negative bacteria. The compounds have potent in vivo efficacy against bloodstream infections caused by E. coli and Klebsiella pneumoniae. The series has favorable properties such as solubility, metabolic stability, and serum protein binding, and lacks pre-existing resistance in clinical isolates. Further development of this class could contribute significantly to the ongoing struggle against antibiotic resistance.